{
  "schema_version": "2.0",
  "description": "归创通桥双语结构化披露数据，涵盖公司简介、2026 年中期业绩、五年财务及分业务收入、经营规模、现金流、股东回报、管理层与主要风险。",
  "description_en": "Bilingual structured disclosure data for Zylox-Tonbridge, covering the company profile, 2026 interim results, five-year financial and segment revenue series, operating scale, cash flow, shareholder returns, management and principal risks.",
  "scope": "HKEX 2021、2023 及 2025 年报，以及截至 2026 年 9 月 12 日复核的 2026 年中期业绩、股东大会投票结果和股份回购公告；年度历史图表截至 FY2025，中期数据单独列示。",
  "methodology_url": "https://pureir.top/#method",
  "usage_notice": "PureIR 为独立、非官方信息平台。本数据帮助读者阅读正式披露，不构成投资建议，也不替代原始文件。",
  "usage_notice_en": "PureIR is an independent, unofficial information platform. This dataset helps readers navigate formal disclosures; it is not investment advice and does not replace the original filings.",
  "publisher": {
    "name": "PureIR",
    "url": "https://pureir.top/"
  },
  "publication_relationship": {
    "type": "unpaid_pilot",
    "labelZh": "免费试点页面",
    "labelEn": "Unpaid pilot profile",
    "disclosureZh": "本页为 PureIR 免费试点页面，由 PureIR 根据正式披露独立整理；公司未付费委托，也未参与评级或投资判断。",
    "disclosureEn": "This is an unpaid PureIR pilot independently prepared from formal disclosure. The company did not commission or pay for the profile and did not participate in any rating or investment judgement."
  },
  "company": {
    "name": "Zylox-Tonbridge Medical Technology Co., Ltd.",
    "name_zh": "归创通桥医疗科技股份有限公司",
    "stock_code": "02190",
    "exchange": "HKEX",
    "fiscal_year_end": "12-31",
    "fiscal_year_note": "财年截至每年 12 月 31 日；2026H1 指截至 2026 年 6 月 30 日止六个月，未经审核。",
    "fiscal_year_note_en": "The fiscal year ends on 31 December. 2026H1 means the unaudited six months ended 30 June 2026.",
    "official_website": "https://www.zyloxtb.com/",
    "official_website_en": "https://www.zyloxtb.com/",
    "investor_relations_contact_url": "https://www.zyloxtb.com/investor-relations/",
    "investor_relations_contact_url_en": "https://www.zyloxtb.com/investor-relations/",
    "investor_relations_email": "ir@zyloxtb.com",
    "investor_relations_email_source": {
      "source_type": "company_website",
      "source_url": "https://www.zyloxtb.com/financial-calender-contact-info.html",
      "source_locator": "Investor relations contact information: email",
      "access_date": "2026-09-12"
    },
    "description": "归创通桥聚焦神经血管及外周血管介入器械的研发、生产与商业化。2026 年上半年收入人民币 632.036 百万元、毛利率 73.4%，期内利润人民币 179.110 百万元；截至 2026 年 6 月 30 日，69 款产品在中国上市，销售网络覆盖逾 3,500 家医院。",
    "description_en": "Zylox-Tonbridge focuses on the R&D, manufacturing and commercialisation of neurovascular and peripheral vascular interventional devices. First-half 2026 revenue was RMB632.036 million, gross margin was 73.4% and profit for the period was RMB179.110 million; at 30 June 2026, 69 products were available in China and its distribution network covered more than 3,500 hospitals.",
    "summary_sources": [
      {
        "label": "2026 年中期财务摘要",
        "label_en": "2026 interim financial highlights",
        "source_type": "hkex_filing",
        "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0820/2026082001477.pdf",
        "pdf_page": 1
      },
      {
        "label": "产品与医院覆盖",
        "label_en": "Products and hospital coverage",
        "source_type": "hkex_filing",
        "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0820/2026082001477.pdf",
        "pdf_page": 3
      },
      {
        "label": "五年财务概要",
        "label_en": "Five-year financial summary",
        "source_type": "hkex_filing",
        "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
        "pdf_page": 8
      }
    ]
  },
  "data_as_of": "2026-06-30",
  "last_reviewed": "2026-09-12",
  "latest_update": {
    "title_zh": "2026 年中期业绩",
    "title_en": "2026 interim results",
    "status_zh": "正式中期业绩 · 未经审核",
    "status_en": "Formal interim results · unaudited",
    "published_zh": "公告发布于 2026 年 8 月 20 日",
    "published_en": "Announcement published 20 August 2026",
    "caveat_zh": "以下数字来自公司正式中期业绩公告，期间为截至 2026 年 6 月 30 日止六个月，未经审核；五年趋势使用截至 FY2025 的经审核年度数据。公司没有就 2026 年中期宣派股息。",
    "caveat_en": "The figures below are from the formal unaudited interim-results announcement for the six months ended 30 June 2026. Five-year trends use audited annual data through FY2025. The company did not declare an interim dividend for 2026."
  },
  "latest_updates": [
    {
      "metric_id": "h1_revenue",
      "label": "中期收入",
      "label_en": "Interim revenue",
      "display": "RMB 632.0m",
      "display_en": "RMB632.0m",
      "period": "2026H1",
      "period_zh": "截至 2026 年 6 月 30 日止六个月",
      "period_en": "Six months ended 30 June 2026",
      "value": 632.036,
      "currency": "RMB",
      "unit": "million",
      "unit_display_zh": "人民币百万元",
      "unit_display_en": "RMB million",
      "detail": "同比增长 31.1%；同期毛利为人民币 463.892 百万元，毛利率 73.4%。",
      "detail_en": "Up 31.1%; gross profit was RMB463.892 million and gross margin was 73.4%.",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0820/2026082001477.pdf",
      "pdf_page": 1
    },
    {
      "metric_id": "h1_profit",
      "label": "中期期内利润",
      "label_en": "Interim profit",
      "display": "RMB 179.1m",
      "display_en": "RMB179.1m",
      "period": "2026H1",
      "period_zh": "截至 2026 年 6 月 30 日止六个月",
      "period_en": "Six months ended 30 June 2026",
      "value": 179.11,
      "currency": "RMB",
      "unit": "million",
      "unit_display_zh": "人民币百万元",
      "unit_display_en": "RMB million",
      "detail": "同比增长 47.8%；公司列报的非国际财务报告准则经调整净利润为人民币 188.812 百万元，同比增长 43.7%。",
      "detail_en": "Up 47.8%; company-reported non-IFRS adjusted net profit was RMB188.812 million, up 43.7%.",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0820/2026082001477.pdf",
      "pdf_page": 1
    },
    {
      "metric_id": "h1_overseas_revenue",
      "label": "海外收入",
      "label_en": "Overseas revenue",
      "display": "RMB 70.6m",
      "display_en": "RMB70.6m",
      "period": "2026H1",
      "period_zh": "截至 2026 年 6 月 30 日止六个月",
      "period_en": "Six months ended 30 June 2026",
      "value": 70.6,
      "currency": "RMB",
      "unit": "million",
      "unit_display_zh": "人民币百万元",
      "unit_display_en": "RMB million",
      "detail": "同比增长 349.3%；公司披露 94 款产品已销往 70 个海外国家及地区。",
      "detail_en": "Up 349.3%; the company disclosed that 94 products were distributed across 70 overseas countries and regions.",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0820/2026082001477.pdf",
      "pdf_page": 4
    }
  ],
  "highlights": [
    {
      "metric_id": "china_products",
      "label": "中国市场产品",
      "label_en": "Products available in China",
      "display": "69 款产品",
      "display_en": "69 products",
      "period": "2026-06-30",
      "period_zh": "截至 2026 年 6 月 30 日",
      "period_en": "At 30 June 2026",
      "value": 69,
      "currency": "N/A",
      "unit": "products",
      "unit_display_zh": "产品",
      "unit_display_en": "products",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0820/2026082001477.pdf",
      "pdf_page": 3
    },
    {
      "metric_id": "covered_hospitals_floor",
      "label": "销售网络覆盖医院",
      "label_en": "Hospitals covered by distribution network",
      "display": "3,500+ 家医院",
      "display_en": "3,500+ hospitals",
      "period": "2026-06-30",
      "period_zh": "截至 2026 年 6 月 30 日",
      "period_en": "At 30 June 2026",
      "value": 3500,
      "currency": "N/A",
      "unit": "hospitals",
      "unit_display_zh": "医院",
      "unit_display_en": "hospitals",
      "comparability_note_zh": "公司披露为超过 3,500 家，此处 canonical value 记录披露下限。",
      "comparability_note_en": "The company disclosed more than 3,500 hospitals; the canonical value records the disclosed floor.",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0820/2026082001477.pdf",
      "pdf_page": 3
    },
    {
      "metric_id": "devices_used_floor",
      "label": "临床使用医疗器械",
      "label_en": "Medical devices used clinically",
      "display": "1.35m+ 件",
      "display_en": "1.35m+ devices",
      "period": "2026-06-30",
      "period_zh": "截至 2026 年 6 月 30 日",
      "period_en": "At 30 June 2026",
      "value": 1350000,
      "currency": "N/A",
      "unit": "devices",
      "unit_display_zh": "医疗器械",
      "unit_display_en": "devices",
      "comparability_note_zh": "公司披露为超过 135 万件，此处 canonical value 记录披露下限。",
      "comparability_note_en": "The company disclosed more than 1.35 million devices; the canonical value records the disclosed floor.",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0820/2026082001477.pdf",
      "pdf_page": 3
    }
  ],
  "narrative": [
    {
      "title": "双业务组合形成介入器械平台",
      "title_en": "Two business lines form an interventional-device platform",
      "text": "公司围绕神经血管和外周血管两条业务线建立研发、生产与商业化能力；2026 年上半年，两项业务收入分别同比增长 20.2% 和 40.0%。",
      "text_en": "The company has built R&D, manufacturing and commercialisation capabilities around neurovascular and peripheral vascular product lines; first-half 2026 revenue from the two businesses grew 20.2% and 40.0%, respectively.",
      "period": "2026H1",
      "value_type": "editorial_synthesis",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0820/2026082001477.pdf",
      "pdf_page": 2
    },
    {
      "title": "产品组合与医院覆盖连接商业化",
      "title_en": "Portfolio breadth and hospital coverage connect commercialisation",
      "text": "截至 2026 年 6 月 30 日，公司披露 69 款产品在中国上市、销售网络覆盖逾 3,500 家医院、临床使用器械超过 135 万件；这些指标反映产品与渠道覆盖，不等同于患者疗效。",
      "text_en": "At 30 June 2026, the company disclosed 69 products available in China, distribution coverage of more than 3,500 hospitals and more than 1.35 million devices used clinically. These figures indicate product and channel reach, not patient outcomes.",
      "period": "2026-06-30",
      "value_type": "editorial_synthesis",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0820/2026082001477.pdf",
      "pdf_page": 3
    },
    {
      "title": "海外业务进入加速阶段",
      "title_en": "Overseas business entered an acceleration phase",
      "text": "2026 年上半年海外收入为人民币 70.6 百万元，同比增长 349.3%；公司披露 94 款产品销往 70 个海外国家及地区，并与合作伙伴覆盖逾 135 个国家及地区。",
      "text_en": "First-half 2026 overseas revenue was RMB70.6 million, up 349.3%. The company disclosed that 94 products were distributed across 70 overseas countries and regions, while partners covered more than 135 countries and regions.",
      "period": "2026H1",
      "value_type": "editorial_synthesis",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0820/2026082001477.pdf",
      "pdf_page": 4
    },
    {
      "title": "盈利与经营现金流同步改善",
      "title_en": "Profit and operating cash flow improved together",
      "text": "FY2025 收入、毛利、归母利润及经营活动现金流净额均高于 FY2024；2026 年上半年收入和期内利润继续同比增长。年度与中期口径分开呈现。",
      "text_en": "FY2025 revenue, gross profit, attributable profit and net operating cash flow all exceeded FY2024 levels, while first-half 2026 revenue and profit continued to grow year on year. Annual and interim periods are presented separately.",
      "period": "FY2025 and 2026H1",
      "value_type": "editorial_synthesis",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0820/2026082001477.pdf",
      "pdf_page": 1,
      "additional_source_type": "hkex_filing",
      "additional_source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "additional_pdf_page": 8
    }
  ],
  "financials": [
    {
      "metric_id": "revenue",
      "label": "收入",
      "label_en": "Revenue",
      "period": "FY2021",
      "value": 177.912,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 8
    },
    {
      "metric_id": "revenue",
      "label": "收入",
      "label_en": "Revenue",
      "period": "FY2022",
      "value": 334.09,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 8
    },
    {
      "metric_id": "revenue",
      "label": "收入",
      "label_en": "Revenue",
      "period": "FY2023",
      "value": 527.754,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 8
    },
    {
      "metric_id": "revenue",
      "label": "收入",
      "label_en": "Revenue",
      "period": "FY2024",
      "value": 782.476,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 8
    },
    {
      "metric_id": "revenue",
      "label": "收入",
      "label_en": "Revenue",
      "period": "FY2025",
      "value": 1057.488,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 8
    },
    {
      "metric_id": "gross_profit",
      "label": "毛利",
      "label_en": "Gross profit",
      "period": "FY2021",
      "value": 131.881,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 8
    },
    {
      "metric_id": "gross_profit",
      "label": "毛利",
      "label_en": "Gross profit",
      "period": "FY2022",
      "value": 252.669,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 8
    },
    {
      "metric_id": "gross_profit",
      "label": "毛利",
      "label_en": "Gross profit",
      "period": "FY2023",
      "value": 384.988,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 8
    },
    {
      "metric_id": "gross_profit",
      "label": "毛利",
      "label_en": "Gross profit",
      "period": "FY2024",
      "value": 559.895,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 8
    },
    {
      "metric_id": "gross_profit",
      "label": "毛利",
      "label_en": "Gross profit",
      "period": "FY2025",
      "value": 762.918,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 8
    },
    {
      "metric_id": "net_profit",
      "label": "归属于公司权益持有人的年度利润 /（亏损）",
      "label_en": "Profit/(loss) attributable to equity holders",
      "period": "FY2021",
      "value": -199.689,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 8
    },
    {
      "metric_id": "net_profit",
      "label": "归属于公司权益持有人的年度利润 /（亏损）",
      "label_en": "Profit/(loss) attributable to equity holders",
      "period": "FY2022",
      "value": -113.555,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 8
    },
    {
      "metric_id": "net_profit",
      "label": "归属于公司权益持有人的年度利润 /（亏损）",
      "label_en": "Profit/(loss) attributable to equity holders",
      "period": "FY2023",
      "value": -78.734,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 8
    },
    {
      "metric_id": "net_profit",
      "label": "归属于公司权益持有人的年度利润 /（亏损）",
      "label_en": "Profit/(loss) attributable to equity holders",
      "period": "FY2024",
      "value": 100.256,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 8
    },
    {
      "metric_id": "net_profit",
      "label": "归属于公司权益持有人的年度利润 /（亏损）",
      "label_en": "Profit/(loss) attributable to equity holders",
      "period": "FY2025",
      "value": 244.37,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 8
    },
    {
      "metric_id": "adjusted_net_profit",
      "label": "非国际财务报告准则经调整净利润 /（亏损）",
      "label_en": "Non-IFRS adjusted net profit/(loss)",
      "period": "FY2021",
      "value": -100.745,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 8
    },
    {
      "metric_id": "adjusted_net_profit",
      "label": "非国际财务报告准则经调整净利润 /（亏损）",
      "label_en": "Non-IFRS adjusted net profit/(loss)",
      "period": "FY2022",
      "value": -25.877,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 8
    },
    {
      "metric_id": "adjusted_net_profit",
      "label": "非国际财务报告准则经调整净利润 /（亏损）",
      "label_en": "Non-IFRS adjusted net profit/(loss)",
      "period": "FY2023",
      "value": 7.033,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 8
    },
    {
      "metric_id": "adjusted_net_profit",
      "label": "非国际财务报告准则经调整净利润 /（亏损）",
      "label_en": "Non-IFRS adjusted net profit/(loss)",
      "period": "FY2024",
      "value": 123.993,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 8
    },
    {
      "metric_id": "adjusted_net_profit",
      "label": "非国际财务报告准则经调整净利润 /（亏损）",
      "label_en": "Non-IFRS adjusted net profit/(loss)",
      "period": "FY2025",
      "value": 273.071,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 8
    }
  ],
  "business_revenue": [
    {
      "metric_id": "neurovascular_revenue",
      "label": "神经血管介入器械收入",
      "label_en": "Neurovascular interventional devices revenue",
      "period": "FY2021",
      "value": 112.271,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2022/0412/2022041201150.pdf",
      "pdf_page": 158
    },
    {
      "metric_id": "peripheral_revenue",
      "label": "外周血管介入器械收入",
      "label_en": "Peripheral vascular interventional devices revenue",
      "period": "FY2021",
      "value": 65.641,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2022/0412/2022041201150.pdf",
      "pdf_page": 158
    },
    {
      "metric_id": "neurovascular_revenue",
      "label": "神经血管介入器械收入",
      "label_en": "Neurovascular interventional devices revenue",
      "period": "FY2022",
      "value": 233.398,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2024/0425/2024042500726.pdf",
      "pdf_page": 22
    },
    {
      "metric_id": "peripheral_revenue",
      "label": "外周血管介入器械收入",
      "label_en": "Peripheral vascular interventional devices revenue",
      "period": "FY2022",
      "value": 100.692,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2024/0425/2024042500726.pdf",
      "pdf_page": 22
    },
    {
      "metric_id": "neurovascular_revenue",
      "label": "神经血管介入器械收入",
      "label_en": "Neurovascular interventional devices revenue",
      "period": "FY2023",
      "value": 381.799,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2024/0425/2024042500726.pdf",
      "pdf_page": 22
    },
    {
      "metric_id": "peripheral_revenue",
      "label": "外周血管介入器械收入",
      "label_en": "Peripheral vascular interventional devices revenue",
      "period": "FY2023",
      "value": 144.653,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2024/0425/2024042500726.pdf",
      "pdf_page": 22
    },
    {
      "metric_id": "neurovascular_revenue",
      "label": "神经血管介入器械收入",
      "label_en": "Neurovascular interventional devices revenue",
      "period": "FY2024",
      "value": 528.511,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 34
    },
    {
      "metric_id": "peripheral_revenue",
      "label": "外周血管介入器械收入",
      "label_en": "Peripheral vascular interventional devices revenue",
      "period": "FY2024",
      "value": 252.419,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 34
    },
    {
      "metric_id": "neurovascular_revenue",
      "label": "神经血管介入器械收入",
      "label_en": "Neurovascular interventional devices revenue",
      "period": "FY2025",
      "value": 676.253,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 34
    },
    {
      "metric_id": "peripheral_revenue",
      "label": "外周血管介入器械收入",
      "label_en": "Peripheral vascular interventional devices revenue",
      "period": "FY2025",
      "value": 379.395,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 34
    }
  ],
  "operating_metrics": [
    {
      "metric_id": "china_products",
      "label": "中国市场产品",
      "label_en": "Products available in China",
      "period": "2026-06-30",
      "value": 69,
      "currency": "N/A",
      "unit": "products",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0820/2026082001477.pdf",
      "pdf_page": 3
    },
    {
      "metric_id": "covered_hospitals_floor",
      "label": "销售网络覆盖医院",
      "label_en": "Hospitals covered by distribution network",
      "period": "2026-06-30",
      "value": 3500,
      "currency": "N/A",
      "unit": "hospitals",
      "comparability_note_zh": "披露下限。",
      "comparability_note_en": "Disclosed floor.",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0820/2026082001477.pdf",
      "pdf_page": 3
    },
    {
      "metric_id": "devices_used_floor",
      "label": "临床使用医疗器械",
      "label_en": "Medical devices used clinically",
      "period": "2026-06-30",
      "value": 1350000,
      "currency": "N/A",
      "unit": "devices",
      "comparability_note_zh": "公司披露超过 135 万件，此处记录披露下限。",
      "comparability_note_en": "The company disclosed more than 1.35 million; the canonical value records the disclosed floor.",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0820/2026082001477.pdf",
      "pdf_page": 3
    },
    {
      "metric_id": "overseas_products",
      "label": "海外销售产品",
      "label_en": "Products distributed overseas",
      "period": "2026-06-30",
      "value": 94,
      "currency": "N/A",
      "unit": "products",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0820/2026082001477.pdf",
      "pdf_page": 4
    },
    {
      "metric_id": "overseas_markets",
      "label": "海外销售国家及地区",
      "label_en": "Overseas countries and regions reached",
      "period": "2026-06-30",
      "value": 70,
      "currency": "N/A",
      "unit": "countries and regions",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0820/2026082001477.pdf",
      "pdf_page": 4
    },
    {
      "metric_id": "partner_market_coverage_floor",
      "label": "合作伙伴覆盖国家及地区",
      "label_en": "Countries and regions covered with partners",
      "period": "2026-06-30",
      "value": 135,
      "currency": "N/A",
      "unit": "countries and regions",
      "comparability_note_zh": "公司披露为超过 135 个，此处记录披露下限。",
      "comparability_note_en": "The company disclosed more than 135; the canonical value records the disclosed floor.",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0820/2026082001477.pdf",
      "pdf_page": 4
    }
  ],
  "cash_flow": [
    {
      "metric_id": "net_operating_cash",
      "label": "经营活动现金流净额",
      "label_en": "Net cash from operating activities",
      "period": "FY2021",
      "value": -116.206,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2022/0412/2022041201150.pdf",
      "pdf_page": 130
    },
    {
      "metric_id": "net_operating_cash",
      "label": "经营活动现金流净额",
      "label_en": "Net cash from operating activities",
      "period": "FY2022",
      "value": -91.323,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2024/0425/2024042500726.pdf",
      "pdf_page": 160
    },
    {
      "metric_id": "net_operating_cash",
      "label": "经营活动现金流净额",
      "label_en": "Net cash from operating activities",
      "period": "FY2023",
      "value": 98.44,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www.hkexnews.hk/listedco/listconews/sehk/2024/0425/2024042500726.pdf",
      "pdf_page": 160
    },
    {
      "metric_id": "net_operating_cash",
      "label": "经营活动现金流净额",
      "label_en": "Net cash from operating activities",
      "period": "FY2024",
      "value": 174.076,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 108
    },
    {
      "metric_id": "net_operating_cash",
      "label": "经营活动现金流净额",
      "label_en": "Net cash from operating activities",
      "period": "FY2025",
      "value": 384.862,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 108
    },
    {
      "metric_id": "available_financial_resources",
      "label": "可用财务资源",
      "label_en": "Available financial resources",
      "period": "2026-06-30",
      "value": 2388.9,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0820/2026082001477.pdf",
      "pdf_page": 46
    },
    {
      "metric_id": "cash_and_equivalents",
      "label": "现金及现金等价物",
      "label_en": "Cash and cash equivalents",
      "period": "2026-06-30",
      "value": 579.7,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0820/2026082001477.pdf",
      "pdf_page": 46
    },
    {
      "metric_id": "term_deposits",
      "label": "定期存款",
      "label_en": "Term deposits",
      "period": "2026-06-30",
      "value": 1516.2,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0820/2026082001477.pdf",
      "pdf_page": 46
    }
  ],
  "shareholder_returns": [
    {
      "metric_id": "final_dividend_per_share",
      "label": "末期股息",
      "label_en": "Final dividend",
      "period": "FY2024",
      "value": 0.1,
      "currency": "RMB",
      "unit": "per share",
      "comparability_note_zh": "FY2024 末期股息于 2025 年股东周年大会获批准并已支付。",
      "comparability_note_en": "The FY2024 final dividend was approved at the 2025 AGM and paid.",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 164
    },
    {
      "metric_id": "final_dividend_per_share",
      "label": "末期股息",
      "label_en": "Final dividend",
      "period": "FY2025",
      "value": 0.22,
      "currency": "RMB",
      "unit": "per share",
      "comparability_note_zh": "FY2025 末期股息于 2026 年 5 月 13 日获股东批准，并于 2026 年上半年支付人民币 72.899 百万元。",
      "comparability_note_en": "The FY2025 final dividend was approved on 13 May 2026, with RMB72.899 million paid in the first half of 2026.",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0820/2026082001477.pdf",
      "pdf_page": 23
    },
    {
      "metric_id": "share_buyback_consideration",
      "label": "中期股份回购代价",
      "label_en": "Interim share-buyback consideration",
      "period": "2026H1",
      "value": 116.26618,
      "currency": "HKD",
      "unit": "million",
      "comparability_note_zh": "截至 2026 年 6 月 30 日止六个月回购 5,514,500 股 H 股，代价不含佣金及其他费用；与每股股息不是同一单位，不作趋势比较。",
      "comparability_note_en": "During the six months ended 30 June 2026, 5,514,500 H shares were repurchased for this consideration, excluding commissions and other expenses. It is not comparable with per-share dividends.",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0820/2026082001477.pdf",
      "pdf_page": 51
    }
  ],
  "management": [
    {
      "name_zh": "赵中",
      "name_en": "Jonathon Zhong Zhao",
      "role_zh": "董事长、执行董事兼首席执行官",
      "role_en": "Chairman, Executive Director and Chief Executive Officer",
      "bio_zh": "2012 年 11 月创立集团，负责整体管理与业务战略；拥有 29 年制药及医疗器械行业经验，曾在 Guilford Pharmaceuticals 及强生旗下 Cordis 从事药械结合产品研发。",
      "bio_en": "Founded the Group in November 2012 and is responsible for overall management and business strategy. He has 29 years of pharmaceutical and medical-device experience, including drug-device combination product development at Guilford Pharmaceuticals and Johnson & Johnson's Cordis.",
      "period": "2025 annual report published 21 April 2026",
      "value_type": "company_disclosure_summary",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 41,
      "portrait_src": "/assets/zyloxtonbridge-zhao-zhong.webp",
      "portrait_alt_zh": "归创通桥董事长兼首席执行官赵中官方头像",
      "portrait_alt_en": "Official portrait of Zylox-Tonbridge Chairman and CEO Jonathon Zhong Zhao",
      "portrait_width": 341,
      "portrait_height": 360,
      "portrait_status": "official_company_website",
      "portrait_source_url": "https://www.zyloxtb.com/about/"
    },
    {
      "name_zh": "谢阳",
      "name_en": "Yang Xie",
      "role_zh": "执行董事兼高级副总裁",
      "role_en": "Executive Director and Senior Vice President",
      "bio_zh": "2016 年 7 月加入集团，负责整体销售、市场及业务战略；此前曾任强生医疗（中国）销售及市场总监，并拥有医疗器械投资与管理经验。",
      "bio_en": "Joined the Group in July 2016 and is responsible for overall sales, marketing and business strategy. He previously served as director of sales and marketing at Johnson & Johnson Medical (China) and has medical-device investment and management experience.",
      "period": "2025 annual report published 21 April 2026",
      "value_type": "company_disclosure_summary",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 41,
      "portrait_src": "/assets/zyloxtonbridge-xie-yang.webp",
      "portrait_alt_zh": "归创通桥执行董事兼高级副总裁谢阳官方头像",
      "portrait_alt_en": "Official portrait of Zylox-Tonbridge Executive Director and Senior Vice President Yang Xie",
      "portrait_width": 341,
      "portrait_height": 360,
      "portrait_status": "official_company_website",
      "portrait_source_url": "https://www.zyloxtb.com/about/"
    },
    {
      "name_zh": "李峥",
      "name_en": "Zheng Li",
      "role_zh": "执行董事兼高级副总裁",
      "role_en": "Executive Director and Senior Vice President",
      "bio_zh": "2016 年 2 月加入集团，负责神经血管业务整体管理与战略；曾任 Covidien（现为美敦力旗下公司）工程师，并具有医疗器械行业研发经验。",
      "bio_en": "Joined the Group in February 2016 and is responsible for overall management and strategy of the neurovascular business. He previously worked as an engineer at Covidien, now part of Medtronic, and has medical-device R&D experience.",
      "period": "2025 annual report published 21 April 2026",
      "value_type": "company_disclosure_summary",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 42,
      "portrait_src": "/assets/zyloxtonbridge-li-zheng.webp",
      "portrait_alt_zh": "归创通桥执行董事兼高级副总裁李峥官方头像",
      "portrait_alt_en": "Official portrait of Zylox-Tonbridge Executive Director and Senior Vice President Zheng Li",
      "portrait_width": 341,
      "portrait_height": 360,
      "portrait_status": "official_company_website",
      "portrait_source_url": "https://www.zyloxtb.com/about/"
    },
    {
      "name_zh": "袁泉卫",
      "name_en": "Quanwei Yuan",
      "role_zh": "首席财务官",
      "role_en": "Chief Financial Officer",
      "bio_zh": "2021 年 1 月加入集团，负责财务管理及企业发展；拥有逾 16 年企业融资及金融市场经验，曾在先声药业及多家跨国投资银行任职。",
      "bio_en": "Joined the Group in January 2021 and oversees financial management and corporate development. He has more than 16 years of corporate-finance and financial-market experience, including roles at Simcere Pharmaceutical and multinational investment banks.",
      "period": "2025 annual report published 21 April 2026",
      "value_type": "company_disclosure_summary",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 46,
      "portrait_src": "/assets/zyloxtonbridge-yuan-quanwei.webp",
      "portrait_alt_zh": "归创通桥首席财务官袁泉卫官方头像",
      "portrait_alt_en": "Official portrait of Zylox-Tonbridge Chief Financial Officer Quanwei Yuan",
      "portrait_width": 341,
      "portrait_height": 360,
      "portrait_status": "official_company_website",
      "portrait_source_url": "https://www.zyloxtb.com/about/"
    }
  ],
  "risks": [
    {
      "title": "产品集中度",
      "title_en": "Product concentration",
      "text": "FY2025 收入仍在很大程度上依赖若干已商业化产品；单一或有限产品的需求、准入或竞争变化可能影响经营表现。",
      "text_en": "FY2025 revenue remained substantially reliant on a limited number of commercialised products; changes in demand, access or competition affecting those products may affect performance.",
      "period": "FY2025",
      "value_type": "company_disclosure_summary",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 9
    },
    {
      "title": "研发与注册转化",
      "title_en": "R&D and regulatory conversion",
      "text": "未来增长依赖候选产品完成临床开发、取得监管批准并成功商业化；失败或重大延迟可能影响业务。",
      "text_en": "Future growth depends on product candidates completing clinical development, securing regulatory approval and being commercialised successfully; failure or material delay may affect the business.",
      "period": "FY2025",
      "value_type": "company_disclosure_summary",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 9
    },
    {
      "title": "集采、招标与价格压力",
      "title_en": "VBP, tendering and pricing pressure",
      "text": "医疗器械市场面临竞争、招标及定价压力，可能影响产品价格、市场份额及盈利能力。",
      "text_en": "Medical-device markets face competition, tendering and pricing pressure, which may affect product prices, market share and profitability.",
      "period": "FY2025",
      "value_type": "company_disclosure_summary",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 9
    },
    {
      "title": "制造质量与合规",
      "title_en": "Manufacturing quality and regulation",
      "text": "产品制造复杂且受严格质量控制，供应、物流、制造或质量问题可能影响业务；医疗器械行业亦受到广泛监管及规则变化影响。",
      "text_en": "Product manufacturing is complex and subject to strict quality controls; supply, logistics, manufacturing or quality issues may affect the business, while the medical-device industry is extensively regulated and exposed to rule changes.",
      "period": "FY2025",
      "value_type": "company_disclosure_summary",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pdf_page": 10
    }
  ],
  "reports": [
    {
      "year": 2025,
      "published": "2026-04-21",
      "title": "Annual Report 2025",
      "title_zh": "2025 年报",
      "url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0421/2026042100514.pdf",
      "pages": 193
    },
    {
      "year": 2023,
      "published": "2024-04-25",
      "title": "Annual Report 2023",
      "title_zh": "2023 年报",
      "url": "https://www.hkexnews.hk/listedco/listconews/sehk/2024/0425/2024042500726.pdf",
      "pages": 241
    },
    {
      "year": 2021,
      "published": "2022-04-12",
      "title": "Annual Report 2021",
      "title_zh": "2021 年报",
      "url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2022/0412/2022041201150.pdf",
      "pages": 201
    }
  ],
  "announcements": [
    {
      "id": "2026-interim-results",
      "published": "2026-08-20",
      "title": "Interim Results for the Six Months Ended June 30, 2026",
      "title_zh": "截至 2026 年 6 月 30 日止六个月中期业绩",
      "url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0820/2026082001477.pdf",
      "pages": 58
    },
    {
      "id": "2026-agm-poll-results",
      "published": "2026-05-13",
      "title": "Poll Results of the Annual General Meeting",
      "title_zh": "股东周年大会投票结果",
      "url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0513/2026051301268.pdf",
      "pages": 7
    },
    {
      "id": "2026-share-repurchase-update",
      "published": "2026-06-15",
      "title": "Update on Share Repurchase",
      "title_zh": "股份回购进展",
      "url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0615/2026061501452.pdf",
      "pages": 2
    }
  ]
}